Bengaluru – Biopharmaceutical company Moderna Inc on Thursday cut its forecast for sales of its COVID-19 vaccine in 2021 by five billion US dollars, equivalent to Rp. 71.7 trillion.
The move comes as the company struggles to complete an increase in production of two inoculated doses of the vaccine that sent its shares down 11 percent in early market trading.
The company said its current sales forecast is in the range of US$15-18 billion (Rp215.3-Rp258.4 trillion) from its previous forecast of US$20 billion.
Deliveries are pegged at between 700-800 million doses per year, up from a previous projection of 800 million to one billion doses throughout 2021.
The company said longer waiting times for international shipments and the temporary impact of expanding its bottling capacity for vaccines could shift some shipments to 2022.
–
:quality(80)/cdn-kiosk-api.telegraaf.nl/f63f3f7e-3d77-11ec-a783-0218eaf05005.jpg?resize=150%2C150&ssl=1)
